Compare LFVN & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFVN | GLQ |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 146.0M |
| IPO Year | 1996 | N/A |
| Metric | LFVN | GLQ |
|---|---|---|
| Price | $4.26 | $7.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 104.8K | 39.9K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | 4.20% | ★ 11.11% |
| EPS Growth | ★ 226.09 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $5.33 |
| 52 Week High | $16.14 | $8.38 |
| Indicator | LFVN | GLQ |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 41.32 |
| Support Level | $3.90 | $7.48 |
| Resistance Level | $5.37 | $7.92 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 13.33 | 45.88 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.